Biomedical subjects

S Inai

Publications and source records attributed to S Inai.

At least 73 records · Page 4Linked to original sources

PubMed1976

Inactivator of the first component of human complement (C1INA). Enhancement of C1INA activity against C1s by acidic mucopolysaccharides.

Acidic mucopolysaccharides enhanced C1INA activity against C1s. The presence of heparin in the reaction mixture of C1INA and C1s markedly enhanced the inactivation of C1s by potentiating C1INA activity. Treatment of serum with C1s resulted in the inactivation of C4 hemolytic activity, but this inactivation of C4 by C1s was prevented by the presence of heparin presumably due to the enhancement of C1INA activity normally present in serum. The other acidic mucopolysaccharides, chondroitin sulfates A, B and C, were also effective on potentiating C1INA activity against C1s, but they were less active than heparin. The enhancement of C1INA activity by heparin was not observed in the reaction between C1INA and plasmin.

Chondroitin Sulfates↗

PubMed1976

Necessity of the divalent cation in the reaction between EAC1-8hu and C9gp.

The reaction of EAC1-8hu and C9gp could not generate E* in 0.09 M EDTA solution. In 0.001 M EDTA solution, EAC1-8hu could not fix C9gp. But E* formation was observed in the buffer containing low concentration of divalent cations. Of the tested cations, Ca++ was most effective and its optimal concentration was 2 X 10(-7) M.

Animals↗

PubMed1976

The serum protein profile in chronic hepatitis, cirrhosis and liver cancer.

Using the single radial immunodiffusion method, the serum levels of IgG, IgA, Ig M, transferrin, haptoglobin, alpha2-macroglobulin, alpha1-antitrypsin and alpha1-acid glycoprotein were estimated in healthy subjects and patients with liver diseases consisting of chronic active and inactive hepatitis, incipient cirrhosis, cirrhosis and primary liver cancer. The results obtained from the statistical analysis of the data were as follows: i) Immunoglobulins and alpha2-macroglobulin in all diseases were higher than those of healthy subjects. ii) The increased transferrin levels were found in chronic active and inactive hepatitis, and the increased alpha1-antitrypsin levels were observed in chronic inactive hepatitis, in incipient cirrhosis in cirrhosis and in primary liver cancer was higher than those of the other liver diseases. iii) Haptoglobulin levels in all diseases except for chronic inactive hepatitis were decreased. iv) alpha1-acid glycoprotein in chronic active hepatitis, in incipient cirrhosis and in cirrhosis were lower than that of healthy subjects. The evaluation of significance for difference of each protein level among disease groups clarified that the decrease of haptoglobin in cirrhosis and the increase of alpha1-antitrypsin in primary liver cancer were characteristic change respectively.

Adult↗

PubMed1976

Differences between plasma and serum complement in patients with chronic liver disease.

Of sixty patients with chronic liver disease, eight with cirrhosis or chronic hepatitis had very low serum CH50 but normal plasma CH50. The complement component profiles of these sera revealed markedly decreased C4 and C2 activities and normal C3T (C3-C9) activities. From these results, it is suggested that the early acting complement components had been non-specifically activated during blood coagulation in these patients. No difference between plasma and serum CH50 was found in patients with hepatitis B(s) antigen.

Adult↗

PubMed1975